Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels
Realizing the reported misuse of human growth hormone (GH), investigation of a safe alternative mechanism for increasing endogenous GH is needed. Several GH secretagogues are available, including GH-releasing peptides (GHRPs) GHRP-2 and GHRP-6, and the GH-releasing hormone analog, sermorelin (SERM)....
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2017-11-01
|
Series: | American Journal of Men's Health |
Online Access: | https://doi.org/10.1177/1557988317718662 |
id |
doaj-cf3ac61894e146eb8f896c2c3fb897c1 |
---|---|
record_format |
Article |
spelling |
doaj-cf3ac61894e146eb8f896c2c3fb897c12020-11-25T03:03:14ZengSAGE PublishingAmerican Journal of Men's Health1557-98831557-98912017-11-011110.1177/1557988317718662Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 LevelsJohn T. Sigalos0Alexander W. Pastuszak1Andrew Allison2Samuel J. Ohlander3Amin Herati4Mark C. Lindgren5Larry I. Lipshultz6Baylor College of Medicine, Houston, TX, USAScott Department of Urology, Baylor College of Medicine, Houston, TX, USAScott Department of Urology, Baylor College of Medicine, Houston, TX, USAUniversity of Illinois at Chicago College of Medicine, Chicago, IL, USAThe Brady Urological Institut, John’s Hopkins Bayview Medical Center Baltimore, MD, USAUniversity of Oklahoma College of Medicine, Department of Urology, Oklahoma City, OK, USAScott Department of Urology, Baylor College of Medicine, Houston, TX, USARealizing the reported misuse of human growth hormone (GH), investigation of a safe alternative mechanism for increasing endogenous GH is needed. Several GH secretagogues are available, including GH-releasing peptides (GHRPs) GHRP-2 and GHRP-6, and the GH-releasing hormone analog, sermorelin (SERM). Insulin-like growth factor 1 (IGF-1) serves as a surrogate marker for GH. Here, the effect of GHRP/SERM therapy on IGF-1 levels is evaluated. A retrospective review of medical records was performed for 105 men on testosterone (T) therapy seeking increases in lean body mass and fat loss who were prescribed 100 mcg of GHRP-6, GHRP-2, and SERM three times daily. Compliance with therapy was assessed, and 14 men met strict inclusion criteria. Serum hormone levels of IGF-1, T, free T (FT), estradiol (E), luteinizing hormone (LH), and follicle-stimulating hormone (FSH) were evaluated. Mean (SD) age of the cohort was 33.2 (2.9) years, and baseline IGF-1 level was 159.5 (26.7) ng/mL. Mean (SD) duration of continuous GHRP/SERM treatment was 134 (88) days. Mean posttreatment IGF-1 level was 239.0 (54.6) ng/mL ( p < .0001). Three of the 14 men were on an aromatase inhibitor and/or tamoxifen prior to treatment and another 4 men were coadministered an aromatase inhibitor and/or tamoxifen during treatment. Inhibition of E production or estrogen receptor blockade resulted in smaller increases in IGF-1 levels. GHRP/SERM therapy increases serum IGF-1 levels with strict compliance to thrice-daily dosing. The results suggest that combination therapy may be beneficial in men with wasting conditions that can improve with increased GH secretion.https://doi.org/10.1177/1557988317718662 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
John T. Sigalos Alexander W. Pastuszak Andrew Allison Samuel J. Ohlander Amin Herati Mark C. Lindgren Larry I. Lipshultz |
spellingShingle |
John T. Sigalos Alexander W. Pastuszak Andrew Allison Samuel J. Ohlander Amin Herati Mark C. Lindgren Larry I. Lipshultz Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels American Journal of Men's Health |
author_facet |
John T. Sigalos Alexander W. Pastuszak Andrew Allison Samuel J. Ohlander Amin Herati Mark C. Lindgren Larry I. Lipshultz |
author_sort |
John T. Sigalos |
title |
Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels |
title_short |
Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels |
title_full |
Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels |
title_fullStr |
Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels |
title_full_unstemmed |
Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels |
title_sort |
growth hormone secretagogue treatment in hypogonadal men raises serum insulin-like growth factor-1 levels |
publisher |
SAGE Publishing |
series |
American Journal of Men's Health |
issn |
1557-9883 1557-9891 |
publishDate |
2017-11-01 |
description |
Realizing the reported misuse of human growth hormone (GH), investigation of a safe alternative mechanism for increasing endogenous GH is needed. Several GH secretagogues are available, including GH-releasing peptides (GHRPs) GHRP-2 and GHRP-6, and the GH-releasing hormone analog, sermorelin (SERM). Insulin-like growth factor 1 (IGF-1) serves as a surrogate marker for GH. Here, the effect of GHRP/SERM therapy on IGF-1 levels is evaluated. A retrospective review of medical records was performed for 105 men on testosterone (T) therapy seeking increases in lean body mass and fat loss who were prescribed 100 mcg of GHRP-6, GHRP-2, and SERM three times daily. Compliance with therapy was assessed, and 14 men met strict inclusion criteria. Serum hormone levels of IGF-1, T, free T (FT), estradiol (E), luteinizing hormone (LH), and follicle-stimulating hormone (FSH) were evaluated. Mean (SD) age of the cohort was 33.2 (2.9) years, and baseline IGF-1 level was 159.5 (26.7) ng/mL. Mean (SD) duration of continuous GHRP/SERM treatment was 134 (88) days. Mean posttreatment IGF-1 level was 239.0 (54.6) ng/mL ( p < .0001). Three of the 14 men were on an aromatase inhibitor and/or tamoxifen prior to treatment and another 4 men were coadministered an aromatase inhibitor and/or tamoxifen during treatment. Inhibition of E production or estrogen receptor blockade resulted in smaller increases in IGF-1 levels. GHRP/SERM therapy increases serum IGF-1 levels with strict compliance to thrice-daily dosing. The results suggest that combination therapy may be beneficial in men with wasting conditions that can improve with increased GH secretion. |
url |
https://doi.org/10.1177/1557988317718662 |
work_keys_str_mv |
AT johntsigalos growthhormonesecretagoguetreatmentinhypogonadalmenraisesseruminsulinlikegrowthfactor1levels AT alexanderwpastuszak growthhormonesecretagoguetreatmentinhypogonadalmenraisesseruminsulinlikegrowthfactor1levels AT andrewallison growthhormonesecretagoguetreatmentinhypogonadalmenraisesseruminsulinlikegrowthfactor1levels AT samueljohlander growthhormonesecretagoguetreatmentinhypogonadalmenraisesseruminsulinlikegrowthfactor1levels AT aminherati growthhormonesecretagoguetreatmentinhypogonadalmenraisesseruminsulinlikegrowthfactor1levels AT markclindgren growthhormonesecretagoguetreatmentinhypogonadalmenraisesseruminsulinlikegrowthfactor1levels AT larryilipshultz growthhormonesecretagoguetreatmentinhypogonadalmenraisesseruminsulinlikegrowthfactor1levels |
_version_ |
1724686843874639872 |